Encouragingly, the powerful synergy of drug repositioning combined with in silico ensemble docking has been demonstrated in two recent publications (24, 25), where, by targeting cyclin-dependent kinase 2 (CDK2), two FDA-approved drugs fluspirilene and adapalene have been rediscovered as anticancer agents in vitro and in vivo for the treatment of hepatocellular and colorectal carcinoma, respectively. The gene discussed is CDK2; the disease is colorectal carcinoma.